Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adnan Mahmood

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP|May 18, 2011
Hypospermatogenesis and spermatozoa maturation arrest in rats induced by mobile phone radiationSultan Ayoub Meo, Muhammad Arif, Shahzad Rashied, et al.
Asia-Pacific Journal of Clinical Oncology|July 3, 2024
PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancerVsevolod Matveev, Xin Gao, Evgeny Kopyltsov, et al.
Ultrasonics Sonochemistry|September 13, 2025
Hierarchical porous carbon biochar nanotubes encapsulated metal nanocrystals with a strong metal-carbon interaction for high-performance supercapacitorsHassan Idris Abdu, Sara Adnan Mahmood, Taslim Aboudou, et al.
Lung|December 13, 2022
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic CoughLorcan McGarvey, Jaclyn A Smith, Alyn Morice, et al.
Mbio|October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing AntibodiesAndrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
The New England Journal of Medicine|December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Journal of the College of Physicians and Surgeons--Pakistan : JCPSP|May 18, 2011
Hypospermatogenesis and spermatozoa maturation arrest in rats induced by mobile phone radiationSultan Ayoub Meo, Muhammad Arif, Shahzad Rashied, et al.
Asia-Pacific Journal of Clinical Oncology|July 3, 2024
PRIORITI: Phase 4 study of triptorelin or active surveillance in high-risk prostate cancerVsevolod Matveev, Xin Gao, Evgeny Kopyltsov, et al.
Ultrasonics Sonochemistry|September 13, 2025
Hierarchical porous carbon biochar nanotubes encapsulated metal nanocrystals with a strong metal-carbon interaction for high-performance supercapacitorsHassan Idris Abdu, Sara Adnan Mahmood, Taslim Aboudou, et al.
Lung|December 13, 2022
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic CoughLorcan McGarvey, Jaclyn A Smith, Alyn Morice, et al.
Mbio|October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing AntibodiesAndrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|July 5, 2022
Repeat subcutaneous administration of casirivimab and imdevimab in adults is well-tolerated and prevents the occurrence of COVID-19Flonza Isa, Eduardo Forleo-Neto, Jonathan Meyer, et al.
The New England Journal of Medicine|December 17, 2020
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19David M Weinreich, Sumathi Sivapalasingam, Thomas Norton, et al.
JAMA Network Open|August 15, 2022
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection: A Phase 2 Dose-Ranging Randomized Clinical TrialCynthia Portal-Celhay, Eduardo Forleo-Neto, Will Eagan, et al.
The Journal of Infectious Diseases|July 27, 2022
Casirivimab and Imdevimab for the Treatment of Hospitalized Patients With COVID-19Selin Somersan-Karakaya, Eleftherios Mylonakis, Vidya P Menon, et al.
Pageof 5